Bispecific agents targeting tumor-cell surface antigens and activating receptors on T lymphocytes are being developed for solid tumors. Effective and safe strategies depend on target specificity and at least relative tumor-tissue confinement of T-cell activation. Novel evidence suggests that constructs targeting HER2 on tumor cells with the aim of providing costimulation (signal-2) to T lymphocytes via CD137 (4-1BB) are safe and can meaningfully invigorate antitumor responses in a proportion of patients.

中文翻译：

---

将 T 细胞共刺激靶向肿瘤细胞表面


针对实体瘤的靶向肿瘤细胞表面抗原和 T 淋巴细胞激活受体的双特异性药物正在开发中。有效和安全的策略取决于靶标特异性和至少 T 细胞活化的相对肿瘤组织限制。新的证据表明，靶向肿瘤细胞上的 HER2 的构建体旨在通过 CD137 （4-1BB） 向 T 淋巴细胞提供共刺激（信号-2）是安全的，并且可以有意义地激发一部分患者的抗肿瘤反应。